{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:50:20Z","timestamp":1761519020914},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T00:00:00Z","timestamp":1312502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12032-011-0035-5","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T18:46:39Z","timestamp":1312483599000},"page":"1495-1501","source":"Crossref","is-referenced-by-count":21,"title":["Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis"],"prefix":"10.1007","volume":"29","author":[{"given":"Nuttapong","family":"Ngamphaiboon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey L.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja P.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellis G.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen B.","family":"Kossoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,5]]},"reference":[{"issue":"8","key":"35_CR1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","volume":"27","author":"S Jones","year":"2009","unstructured":"Jones S, Holmes FA, O\u2019Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009;27(8):1177\u201383. doi: 10.1200\/JCO.2008.18.4028 .","journal-title":"J Clin Oncol"},{"issue":"2","key":"35_CR2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdq609","volume":"22","author":"M Aapro","year":"2011","unstructured":"Aapro M, Bernard-Marty C, Brain EG, Batist G, Erdkamp F, Krzemieniecki K, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 2011;22(2):257\u201367. doi: 10.1093\/annonc\/mdq609 .","journal-title":"Ann Oncol"},{"key":"35_CR3","doi-asserted-by":"crossref","unstructured":"Ngamphaiboon N, Edge SB, Groman A, Wilding GE, Ademuyiwa FO, Levine EG, Watroba N, O\u2019Connor TL. Factors affecting delivery of planned chemotherapy for breast cancer in older women. In: The 33rd Annual San Antonio Breast Cancer Symposium. 2010;abstract#851603.","DOI":"10.1158\/0008-5472.SABCS10-P5-13-08"},{"issue":"34","key":"35_CR4","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","volume":"24","author":"SE Jones","year":"2006","unstructured":"Jones SE, Savin MA, Holmes FA, O\u2019Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381\u20137. doi: 10.1200\/JCO.2006.06.5391 .","journal-title":"J Clin Oncol"},{"issue":"6","key":"35_CR5","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","volume":"34","author":"WT Hughes","year":"2002","unstructured":"Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730\u201351. doi: 10.1086\/339215 .","journal-title":"Clin Infect Dis"},{"issue":"4","key":"35_CR6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00520-010-0843-8","volume":"19","author":"A Chan","year":"2011","unstructured":"Chan A, Fu WH, Shih V, Coyuco JC, Tan SH, Ng R. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer. 2011;19(4):497\u2013504. doi: 10.1007\/s00520-010-0843-8 .","journal-title":"Support Care Cancer"},{"key":"35_CR7","doi-asserted-by":"crossref","unstructured":"Kotasek D. Febrile neutropenia rates during docetaxel and cyclophosphamide (TC) adjuvant therapy in early breast cancer (EBC). J Clin Oncol 2011;29(suppl; abstr 1101).","DOI":"10.1200\/jco.2011.29.15_suppl.1101"},{"key":"35_CR8","doi-asserted-by":"crossref","unstructured":"Soni A, Brufsky A, Jankowitz RC, Rastogi P, Vogel VG, Puhalla S Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic. J Clin Oncol. 2011;29(suppl; abstr 9061).","DOI":"10.1200\/jco.2011.29.15_suppl.9061"},{"issue":"2","key":"35_CR9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3747\/co.v17i2.498","volume":"17","author":"T Vandenberg","year":"2010","unstructured":"Vandenberg T, Younus J, Al-Khayyat S. Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis. Curr Oncol. 2010;17(2):2\u20133.","journal-title":"Curr Oncol"},{"issue":"8","key":"35_CR10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jjco\/hyp050","volume":"39","author":"D Takabatake","year":"2009","unstructured":"Takabatake D, Taira N, Hara F, Sien T, Kiyoto S, Takashima S, et al. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol. 2009;39(8):478\u201383. doi: 10.1093\/jjco\/hyp050 .","journal-title":"Jpn J Clin Oncol"},{"key":"35_CR11","doi-asserted-by":"crossref","unstructured":"Myers R, Higgins B, Jeffrey M, Mova L, Rajagopal S, Jones G, Stakiw J. Chemotherapy induced febrile neutropenia of docetaxel with cyclophosphamide (TC) for adjuvant therapy of breast cancer in the community-reality check. In: The 32nd Annual San Antonio Breast Cancer Symposium. 2009;Abstract#2092.","DOI":"10.1158\/0008-5472.SABCS-09-2092"},{"key":"35_CR12","unstructured":"NCCN. NCCN Guideline V1.2011 Myeloid Growth Factors. http:\/\/wwwnccnorg\/professionals\/physician_gls\/pdf\/myeloid_growthpdf (2011)."},{"issue":"1","key":"35_CR13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8\u201332. doi: 10.1016\/j.ejca.2010.10.013 .","journal-title":"Eur J Cancer"},{"issue":"5","key":"35_CR14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"11","key":"35_CR15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","volume":"2","author":"W Hryniuk","year":"1984","unstructured":"Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2(11):1281\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"35_CR16","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178\u201384. doi: 10.1200\/JCO.2005.09.102 .","journal-title":"J Clin Oncol"},{"key":"35_CR17","unstructured":"NCI. Common Terminology Criteria for Adverse Events (CTCAE V.4). http:\/\/evsncinihgov\/ftp1\/CTCAE\/CTCAE_403_2010-06-14_QuickReference_85x11pdf (2009)."},{"issue":"3","key":"35_CR18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","volume":"77","author":"H Wildiers","year":"2011","unstructured":"Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol. 2011;77(3):221\u201340. doi: S1040-8428(10)00032-6 .","journal-title":"Crit Rev Oncol Hematol"},{"issue":"22","key":"35_CR19","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1002\/cncr.24560","volume":"115","author":"M Shayne","year":"2009","unstructured":"Shayne M, Culakova E, Wolff D, Poniewierski MS, Dale DC, Crawford J, et al. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer. 2009;115(22):5319\u201328. doi: 10.1002\/cncr.24560 .","journal-title":"Cancer"},{"issue":"19","key":"35_CR20","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265\u201374. doi: 10.1200\/JCO.2005.04.173 .","journal-title":"J Clin Oncol"},{"issue":"21","key":"35_CR21","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158\u201367. doi: 10.1200\/JCO.2006.08.8823 .","journal-title":"J Clin Oncol"},{"issue":"6","key":"35_CR22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-147-6-200709180-00010","volume":"147","author":"L Sung","year":"2007","unstructured":"Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007;147(6):400\u201311.","journal-title":"Ann Intern Med"},{"key":"35_CR23","first-page":"CD003189","volume":"4","author":"J Bohlius","year":"2008","unstructured":"Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2008;4:CD003189. doi: 10.1002\/14651858.CD003189 .","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"35_CR24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-9343(02)01036-7","volume":"112","author":"GH Lyman","year":"2002","unstructured":"Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112(5):406\u201311.","journal-title":"Am J Med"},{"issue":"3","key":"35_CR25","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cncr.24773","volume":"116","author":"N Lathia","year":"2010","unstructured":"Lathia N, Mittmann N, DeAngelis C, Knowles S, Cheung M, Piliotis E, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer. 2010;116(3):742\u20138. doi: 10.1002\/cncr.24773 .","journal-title":"Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0035-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-011-0035-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0035-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T19:44:06Z","timestamp":1560455046000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-011-0035-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1007\/s12032-011-0035-5","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,5]]}}}